Search

By Industry Solutions (1)
By Phase (1)
By Therapeutic Area (2)
Keywords (10)

Filters

Showing results 81 - 96 of 399 for .

Showing results 81 - 96 of 399 for .

Determination of Carbonyl Compounds in Gas Vapour Phase in Phosphate Buffered Saline by LC-MS/MS
CORESTA 2018 -- Carbonyl and di-ketone compounds are listed as harmful and potentially harmful constituents (HPHCs) and can be found in cigarette smoke and next generation products (NGPs). When conducting in vitro toxicology tests to evaluate the relative toxicity and mutagenicity of cigarettes or NGPs, one of the testing paradigms is to conduct testing with the gas vapour phase (GVP), with the dose quantified in terms of equivalent mg TPM. There is currently no standardised method for...
Simultaneous Measurement of Cilia Beat Frequency, Goblet Cell Hyperplasia and TEER Endpoints in EpiAirway-FT Treated Tissues May Reveal Underlying Toxicity Mechanisms In Vitro
CORESTA 2018 -- In the airway epithelium, Goblet cells produce mucus to enable the mucociliary clearance of unwanted particles from the bronchi and trachea. Hyperplasia of goblet cells (GCH) is one of the many respiratory epithelial responses to numerous environmental challenges (e.g. cigarette smoke, air pollution, viral infection) and is commonly observed in respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma. The changes in the airway epithelium caused by...
Contribution of UGT1A1, CYP2A6, CYP2C9 and CYP3A4 in Metabolism of Belinostat
ISSX 2018 -- Belinostat, a potent inhibitor of class I and class II histone deacetylase enzymes, has been approved for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. The chemical structure and metabolic pathway of belinostat are presented in Figure 1. This study aimed to assess contribution of UGT1A1, CYP2A6, CYP2C9 and CYP3A4 in metabolism of 14C-belinostat using in vitro test systems.
Validation of Alzheimer's Biomarkers: β-Amyloid 1-42 and Total Tau in CSF by Automated CLEIA on Lumipulse G 1200 Platform
AACC 2018 -- Guideline for Alzheimer's disease diagnosis (AD) suggests using AD biomarkers for the pre-symptomatic and symptomatic phases. Cerebrospinal fluid (CSF) level of β-amyloid 1-42 (Aβ-42) and total Tau proteins have been increasingly included in the diagnostic process of Alzheimer's disease. Aβ-42 is cleaved from amyloid precursor protein which ends up as aggregates in the brain, Aβ-42 plaque depositions are widely used to characterize AD. Analysis of Aβ-42 in CSF of AD patients...
Validation of New Access 3rd International Standard Thyroid Stimulating Hormone (TSH) Assay and its Correlation with Access Hypersensitive TSH and Siemens Ultra TSH Assays
AACC 2018 -- TSH is a glycoprotein consisting of two non-covalently bound subunits; an alpha and beta subunit. TSH released from the anterior pituitary is the principle regulator of thyroid function by stimulating the synthesis and release of thyroid hormones. Clinical use of measurement of TSH is for the assessment of thyroid status. The sensitivity of the TSH assay has increased substantially over last several decades leading to the current 3rd generation TSH assays. Current TSH methods...
Making Sense of a B Cell Marker on T Cells: Validation of a Flow Cytometric Method Measuring CD20 Expression on T Cell Subsets
ICCS 2018 -- Depletion of B cells using anti-CD20 drugs has become a major therapeutic approach for the treatment of Multiple Sclerosis (MS) and B cell lymphomas. While CD20 has been extensively studied as a classical B cell marker, several studies have lent support to the existence of a subset of CD3+ T cells expressing CD20. Furthermore, CD20+ T cells appear to constitute a significant fraction of Th17 cells in Rheumatoid Arthritis patients compared with healthy individuals. Although the...
Development of an LC-MS/MS Method for Creatinine Measurement in Icteric Subjects
AACC 2018 -- Clinical trial subjects represent a unique patient population in that the vast majority of patients present in the diseased state, versus the primarily non-diseased state served by reference and hospital laboratories. Central laboratories serving clinical trials are under extraordinary pressure to report laboratory results for this vulnerable population. One example of this challenge resides in the determination of serum creatinine in icteric patients due to hepatic...
Challenges of Cross-Lab Validation for Sphingolipids Biomarker Assays with Multiple Isomers in Human Dried Blood Spots
AAPS PharmSci 360 2018 -- Total ceramide (11 isomers, CER) and total sphingomyelin (17 isomers, SPM) are under evaluation as biomarkers in human dried blood spots (DBS) for monitoring patients with Niemann-Pick disease, who have received enzyme replacement therapy. The two bioanalytical methods used for several clinical trials in the sponsor's lab were transferred to Covance. Both methods were cross-validated at Covance and met precision and accuracy acceptance criteria using purified...
Drug Development Solutions Distinctly for Progressive Biopharma Ventures
Experience drug development - your way. Welcome to a unique experience, one that's Designed Around You®. Where you control your journey from start to finish. Regardless of where you are and how far you aspire to go, choose the options that make the most of your endeavor.
Drug Abuse-Related Studies
GLP & efficacy/investigative assessment studies are available at Covance.
Early Metabolite (MetID)
Enhance your lead candidate properties for early decision-making
In Vitro Cardiac Safety Assessment
Comprehensive end-to-end testing for hERG
A Fully Compliant, DDI Solution
Successfully navigate FDA regulations for in vitro metabolism and drug transporters
Connect Right From the Start: MarketPlace for Asset Providers
Find the right partner with the desire and resources to help you realize your asset's potential. Through our private, secure and exclusive online portal, you can share information about your asset to attract potential investors or partners.
Meet Your Next Novel Candidate: MarketPlace for Asset Seekers
Find high-quality, novel asset(s) easier. Exclusive access to our unique, proprietary and secure digital platform enables you to review summary information and connect with an array of Asset Providers.
Patient Access to Gene Therapies
Patient access to potentially curative gene therapies hinges on close collaboration between healthcare providers, manufacturers and payers to overcome key clinical, manufacturing, logistical and reimbursement barriers.